Ignite Creation Date:
2025-12-26 @ 1:19 PM
Ignite Modification Date:
2026-03-09 @ 4:14 AM
Study NCT ID:
NCT05068206
Status:
UNKNOWN
Last Update Posted:
2021-10-20
First Post:
2021-09-24
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx
Sponsor:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
ALTN-AK105-II-04
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None